Definium's LSD Drug Shows Strong Anxiety Reduction in Second Late-Stage Trial
DFTX has more than doubled off its 52-week low of $8.773.
Summary
Definium's DT120, an LSD-based treatment for generalized anxiety disorder, reduced anxiety scores by 9.8 points versus 4.7 for placebo after 12 weeks in its second Phase 3 trial. The 100-microgram dose showed higher efficacy than the 50-microgram dose, and benefits appeared as early as day 2. The company plans to file a marketing application with the FDA in the first half of 2027. This follows the initial Voyage study results reported in August and the recent Breakthrough Therapy designation for DT120 in major depressive disorder. The detailed data strengthens the case for approval in a condition where many programs have failed, and the planned filing timeline gives investors a concrete milestone. Additionally, the company granted inducement stock options.
At the time of this announcement, DFTX was trading at $41.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $8.77 to $49.70. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.